Medical device company HTG Molecular Diagnostics has signed a research agreement with Centre Leon Berard, a non-profit organisation involved in molecular profiling studies, to advance precision medicine.

The research project will utilise the HTG EdgeSeq oncology biomarker panel to retrospectively characterise immunologic profiles from advanced malignant tumour samples collected in the ProfiLER study.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Collaboration enables immunogenic profiling of tumours and allows for the identification of biomarkers with a potential predictive value and for detecting whether certain genetic disorders are linked to immunity status alteration.

Israel-based compact MRI systems developer Aspect Imaging has raised $30m with the help of the company’s existing investors.

Funds will be used to continue the development of its Embrace Neonatal MRI system and its new Stroke-dedicated MRI System.

See Also:

Digital health care company Livongo Health and glycemic management solutions company Glytec have partnered to develop a new eGlycemic Management System (eGMS) for Livongo members.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The two companies will work to deliver an expanded diabetes management solution that includes insulin titration.

The expanded solution will provide improved health for diabetic patients, by integrating medication data, monitoring and optimised medication adherence.

Diabetes-related medical technology company Cellnovo has signed a worldwide commercial licensing agreement with TypeZero Technologies.

"Collaboration enables immunogenic profiling of tumours and allows for the identification of biomarkers with a potential predictive value and for detecting whether certain genetic disorders are linked to immunity status alteration."

The agreement includes the integration of TypeZero Technologies' artificial pancreas (AP) technology, known as inControl AP, into Cellnovo's Bluetooth-enabled mobile diabetes management system.

Cellnovo will be responsible for the commercialisation of the product, which is expected to be launched in 2018.

Medical technology company NeuroTronik has raised $23.1m in a series B preferred stock financing round led by Boston Scientific Group.

Financing is in line with the company’s project-plan milestones and will be used to advance the development of its NeuroTronik CANS Therapy system, an investigational therapy to improve the treatment of acute heart failure (AHF). It will also help the company to receive CE Mark approval for the therapy system.